Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis

A kit comprising a pharmaceutical composition for slowing progression of, and/or treating, a fibrotic disease in a subject in need thereof, wherein said pharmaceutical composition is formulated for treating pulmonary fibrosis, liver fibrosis, skin fibrosis or cardiac fibrosis, and wherein said pharmaceutical composition comprises a pharmaceutically-acceptable carrier and a compound represented by the formula:

• or a pharmaceutically acceptable salt thereof, wherein
• A is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)—(CH2)n-CH3 or CH(OH)—(CH2)n-CH3 wherein n is 3 or 4;
• R1 is H, OH or F;
• R2 is H, OH, F or CH2—OH;
• R3 is CH2Ph;
• R4 is H, OH or F;
• Q is
• 1) (CH2)mC(O)OH wherein m is 1 or 2,
• 2) CH(CH3)C(O)OH,
• 3) C(CH3)2C(O)OH,
• 4) CH(F)—C(O)OH,
• 5) CF2—C(O)OH, or
• 6) C(O)—C(O)OH;
• wherein the kit further comprises instructions for administering a therapeutically effective amount of the compound to the subject suffering from said fibrotic disease;
• and wherein the fibrotic disease is pulmonary fibrosis, liver fibrosis, skin fibrosis or cardiac fibrosis.